(DRNA) Panel on RNAi Therapeutics At 16th Annual BIO CEO and Investor Conference

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16^th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company’s President and CEO, is scheduled to take part in a Therapeutic Workshop entitled: “Delivering the [RNAi] Goods” to be held on Monday, February 10^th, at 10:30 a.m. Eastern Standard Time.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.